These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 31413897)
1. Successful Treatment of Primary Orthostatic Tremor Using Perampanel. Wadhwa A; Schaefer SM Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31413897 [TBL] [Abstract][Full Text] [Related]
2. Complete Resolution of Symptoms of Primary Orthostatic Tremor with Perampanel. Ruiz-Julián M; Orozco JL; Gironell A Tremor Other Hyperkinet Mov (N Y); 2018; 8():552. PubMed ID: 29686940 [TBL] [Abstract][Full Text] [Related]
3. Primary Orthostatic Tremor: Experience of Perampanel Use in 20 Patients. Gironell A; Marín-Lahoz J Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31673479 [TBL] [Abstract][Full Text] [Related]
4. Remarkable improvement of primary orthostatic tremor using perampanel. Grobe-Einsler M; Kaut O Neurol Res Pract; 2020; 2():3. PubMed ID: 33324909 [TBL] [Abstract][Full Text] [Related]
5. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316 [TBL] [Abstract][Full Text] [Related]
6. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001 [TBL] [Abstract][Full Text] [Related]
9. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657 [TBL] [Abstract][Full Text] [Related]
10. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. Zaccara G; Giovannelli F; Cincotta M; Iudice A Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002 [TBL] [Abstract][Full Text] [Related]
11. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Garcia-Borreguero D; Cano I; Granizo JJ Sleep Med; 2017 Jun; 34():105-108. PubMed ID: 28522077 [TBL] [Abstract][Full Text] [Related]
12. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772 [TBL] [Abstract][Full Text] [Related]
13. Introduction: Perampanel--new mode of action and new option for patients with epilepsy. Steinhoff BJ Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689 [TBL] [Abstract][Full Text] [Related]
14. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings. Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650 [TBL] [Abstract][Full Text] [Related]
15. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398 [TBL] [Abstract][Full Text] [Related]
16. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability. Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of perampanel: a review of clinical trial data. Serratosa JM; Villanueva V; Kerling F; Kasper BS Acta Neurol Scand Suppl; 2013; (197):30-5. PubMed ID: 23480154 [TBL] [Abstract][Full Text] [Related]
19. [Orthostatic tremor as a cause of dysequilibrium]. Rudzińska M; Wójcik M; Szczudlik A Neurol Neurochir Pol; 2009; 43(1):96-100. PubMed ID: 19353450 [No Abstract] [Full Text] [Related]
20. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy. El Desoky ES Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]